SANA Stock Cash Flow Statements

Sana Biotechnology Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Sana Biotechnology Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31

operating activities:
net income	-93,800,000	-49,389,000	-49,069,000	-59,924,000	-50,291,000	-107,475,000	-88,117,000	984,000	-113,999,000	-82,123,000	-80,443,000	-85,120,000	-72,465,000	-31,448,000	-110,731,000	-83,263,000	18,683,000	-180,617,000
adjustments to reconcile net income to net cash from operating activities:
depreciation	2,857,000	3,649,000		4,057,000				4,499,000	4,448,000	4,346,000	4,195,000	4,016,000	3,800,000	3,614,000	3,335,000	2,882,000	2,606,000	2,247,000
stock-based compensation expense	6,629,000	7,022,000	6,436,000	10,770,000	11,380,000	9,092,000	7,931,000	9,003,000	9,848,000	8,751,000	10,591,000	10,080,000	9,911,000	7,755,000	7,313,000	5,950,000	4,941,000	4,158,000
change in the estimated fair value of contingent consideration	6,300,000	1,864,000	-2,888,000	235,000	-3,369,000	5,384,000	6,450,000	-58,578,000	5,895,000	5,460,000	9,249,000	-8,255,000	-3,830,000	-528,000	21,762,000	-8,476,000
change in the estimated fair value of success payment liabilities	3,962,000	93,000	-10,559,000	-5,732,000	-24,575,000	32,623,000	385,000	-24,037,000	20,784,000	-5,340,000	-14,703,000	2,193,000	-14,098,000	-54,910,000	-31,667,000	25,229,000
non-cash expense for operating lease right-of-use assets	2,230,000	2,233,000	2,180,000	2,114,000	2,049,000	3,338,000	3,234,000	3,276,000	3,401,000	3,354,000	3,247,000	3,177,000	3,076,000	2,606,000	2,247,000	1,759,000	1,440,000	1,398,000
impairment of long-lived assets
other non-cash items	-2,523,000	-3,271,000	-3,225,000	-2,995,000	21,000	-4,879,000	-3,350,000	-3,874,000	-3,175,000	-2,913,000	-2,615,000	-2,961,000	-2,289,000	-1,437,000	-821,000	-233,000	-1,009,000	-1,013,000
changes in operating assets and liabilities:
prepaid expenses and other assets	-628,000	1,368,000	3,268,000	678,000	-5,079,000	-2,380,000	2,583,000	132,000	5,534,000	-106,000	-6,557,000	1,226,000	2,534,000	-3,191,000	2,124,000	-1,266,000	-105,000	-1,614,000
operating lease right-of-use assets and liabilities	-972,000	891,000	1,750,000	165,000	1,622,000	5,804,000	8,830,000	685,000	1,452,000	-8,000	-22,000	1,473,000	-261,000	372,000	60,000	1,642,000
accounts payable	1,225,000	-4,224,000	2,281,000	-507,000	667,000	-1,064,000	-1,336,000	2,276,000	441,000	-354,000	-1,086,000	1,481,000	-1,254,000	1,917,000	-1,663,000	1,770,000	-1,972,000	1,599,000
accrued expenses and other liabilities	-2,992,000	-8,893,000	-3,028,000	-680,000	5,139,000	-9,821,000	167,000	2,084,000	6,570,000	-10,339,000	2,077,000	7,894,000	3,398,000	-2,459,000	-2,058,000	3,520,000	7,499,000	-3,121,000
net cash from operating activities	-33,101,000	-48,657,000	-47,161,000	-51,819,000	-58,541,000	-65,632,000	-51,959,000	-63,550,000	-58,801,000	-79,272,000	-76,067,000	-64,796,000	-71,478,000	-77,709,000	-110,099,000	-50,486,000	-40,556,000	-49,913,000
capex	112,000	-136,000	-436,000	-7,211,000	-18,055,000	-7,470,000	-14,508,000	5,747,000	-592,000	-1,208,000	-5,777,000	-5,287,000	-4,470,000	-4,108,000	-5,418,000	-8,247,000	-9,899,000	-3,283,000
free cash flows	-32,989,000	-48,793,000	-47,597,000	-59,030,000	-76,596,000	-73,102,000	-66,467,000	-57,803,000	-59,393,000	-80,480,000	-81,844,000	-70,083,000	-75,948,000	-81,817,000	-115,517,000	-58,733,000	-50,455,000	-53,196,000
investing activities:
purchases of marketable securities	0	-1,682,000	-13,076,000	-35,970,000	-62,625,000	-114,393,000	-26,127,000	-60,350,000	-50,836,000	-20,431,000	-15,105,000	-17,622,000	-20,286,000	-25,675,000	-76,950,000	-248,886,000	-120,740,000	-44,811,000
proceeds from maturities of marketable securities	7,186,000	18,168,000	60,600,000	81,838,000	81,499,000	53,010,000	55,483,000	113,931,000	95,040,000	85,334,000	108,135,000	53,831,000	102,407,000	45,753,000
purchases of property and equipment	112,000	-136,000	-436,000	-4,093,000	-13,056,000	-15,845,000	-14,046,000	-2,233,000	-1,577,000	-2,176,000	-4,602,000	-4,350,000	-4,391,000	-7,533,000	-5,202,000	-8,064,000	-10,156,000	-6,440,000
proceeds from disposal of assets	382,000	253,000
net cash from investing activities	7,680,000	16,603,000	47,088,000	41,775,000	5,818,000	-77,228,000	15,310,000	51,348,000	42,627,000	62,727,000	88,428,000	31,859,000	77,730,000	12,545,000	-73,661,000	-185,904,000	-35,324,000	49,091,000
financing activities:
proceeds from employee stock purchase plan and exercise of stock options	333,000	1,127,000	699,000	1,939,000	3,438,000	4,929,000					1,184,000	897,000	1,579,000	652,000
proceeds related to common stock financings
proceeds (principal payments), net for tenant improvement loan
net cash from financing activities	561,000	982,000	643,000	2,082,000	10,627,000	186,397,000	1,718,000	187,000	29,505,000	236,000	1,061,000	1,621,000	1,579,000	652,000	3,119,000	1,596,000	333,000	626,703,000
net increase in cash, cash equivalents, and restricted cash	-24,860,000	-31,072,000			-42,096,000	43,537,000					13,422,000	-31,316,000	7,831,000	-64,512,000	-180,641,000	-234,794,000	-75,547,000	625,881,000
cash, cash equivalents, and restricted cash at beginning of period	0	131,398,000	0	0	0	137,349,000	0	0	0	187,273,000	0	0	0	261,848,000	0	0	0	126,949,000
cash, cash equivalents, and restricted cash at end of period	-24,860,000	100,326,000	570,000	-7,962,000	-42,096,000	180,886,000	-34,931,000	-12,015,000	13,331,000	170,964,000	13,422,000	-31,316,000	7,831,000	197,336,000	-180,641,000	-234,794,000	-75,547,000	752,830,000
supplemental cash flow information:
purchases of property and equipment included in accounts payable and accrued liabilities				-3,118,000	-4,999,000	8,375,000	-462,000	7,980,000	985,000	968,000	-1,175,000	-937,000	-79,000	3,425,000	-216,000	-183,000	257,000	3,157,000
cash received for tenant improvement allowances	0	891,000	165,000	0	1,223,000	6,121,000
derecognition of operating lease right-of-use assets for lease modification
proceeds (fees) related to common stock financings		-60,000
principal payments for tenant improvement loan		-85,000
depreciation and impairment of long-lived assets						3,746,000
proceeds from issuance of common stock from equity financings			0	-29,000	-439,000	181,468,000
proceeds from tenant improvement loan			-56,000	172,000
net decrease in cash, cash equivalents, and restricted cash			570,000					-12,015,000	13,331,000	-16,309,000
reconciliation of cash, cash equivalents and restricted cash:
cash and cash equivalents
restricted cash
long-term restricted cash
total cash, cash equivalents, and restricted cash
operating lease right-of-use assets obtained in exchange for lease obligations							0	0	0	8,984,000	0	0	17,642,000	3,431,000
derecognition of operating lease right-of-use asset for lease termination							0
derecognition of operating lease right-of-use asset for lease modification			-899,000	0
other investing activities
proceeds from initial public offering, net of issuance costs
proceeds from issuance of common stock							1,707,000	192,000	2,491,000	236,000
proceeds from issuance of common stock under at the market offering							11,000	-5,000
remeasurement of operating lease right-of-use asset for lease modification											0	0
cash received for amounts related to tenant improvement allowances								1,100,000			0	1,473,000	0	541,000
proceeds from issuance of convertible preferred stock, net of issuance costs
proceeds from at the market offering of common stock, net of issuance costs											-123,000
reconcilition of cash, cash equivalents and restricted cash:
deferred income tax
non-cash expense in connection with license agreement and asset acquisition
proceeds from sales and maturities of marketable securities															13,065,000	71,046,000	95,572,000	100,342,000
acquisitions, net of cash acquired
issuance of convertible preferred stock for acquisition
proceeds from initial public offering of common stock, net of offering costs																0	0	626,405,000
proceeds from exercise of stock options																1,596,000	333,000	298,000
supplemental cash flow disclosures:
right-of-use assets obtained in exchange for operating lease liabilities
cash received from lessor for tenant improvement allowance																1,774,000
tenant improvement allowance included in operating lease liabilities																-497,000	-3,580,000	8,515,000
change in fair value of contingent consideration																		11,393,000
change in fair value of success payment liabilities																		115,657,000
non-cash expense in connection with license agreement
non-cash expense for equity issuance in connection with license agreements
non-cash expense in connection with asset acquisition
issuance of promissory note
payment of contingent consideration
tenant improvement allowance included in contra-lease liability

We provide you with 20 years of cash flow statements for Sana Biotechnology stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Sana Biotechnology stock. Explore the full financial landscape of Sana Biotechnology stock with our expertly curated income statements.

The information provided in this report about Sana Biotechnology stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.